2008 Fiscal Year Final Research Report
Analysis of lenalidomide-resistance in multiple myeloma
Project/Area Number |
19790673
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Hematology
|
Research Institution | Sapporo Medical University |
Principal Investigator |
YASUI Hiroshi Sapporo Medical University, 医学部, 研究員 (40448593)
|
Project Period (FY) |
2007 – 2008
|
Keywords | 血液内科学 / 多発性骨髄腫 / サリドマイド誘導体 |
Research Abstract |
多発性骨髄腫におけるレナリドマイド耐性の機序解析を行うため、レナリドマイド感受性骨髄腫細胞株から、レナリドマイド抵抗性の細胞株を樹立した。これら細胞株間の遺伝子発現の相違をDNAアレイにより解析し、レナリドマイドによる抗骨髄腫効果とレナリドマイド抵抗性の機序とを検討した。これらの機序解析は、レナリドマイド抵抗性を克服する新規併用療法を開発するにあたり、有用な情報となると考えられる。
|
-
[Journal Article] Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.2009
Author(s)
Nojima M, Maruyama R, Yasui H, Suzuki H, Maruyama Y, Tarasawa I, Sasaki Y, Asaoku H, Sakai H, Hayashi T, Mori M, Imai K, Tokino T, Ishida T, Toyota M, Shinomura Y
-
Journal Title
Clin Cancer Res 15(13)
Pages: 4356-64
Peer Reviewed
-
[Journal Article] SNX-2112, a selective hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematological tumors by abrogating signaling via Akt and ERK.2009
Author(s)
Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S, Anderson KC
-
Journal Title
Blood 113(4
Pages: 846-55
Peer Reviewed
-
[Journal Article] The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.2009
Author(s)
Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dalken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC
-
Journal Title
Clin Cancer Res 15(12)
Pages: 4028-37
Peer Reviewed
-
-
[Journal Article] Fatty acid synthase is a novel therapeutic target in multiple myeloma.2008
Author(s)
Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, Yasui H, Enatsu S, Pozzi S, Breitkreutz I, Cirstea D, Santo L, Richardson P, Anderson KC
-
Journal Title
Br J Haematol 141(5)
Pages: 659-71
Peer Reviewed
-
[Journal Article] Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.2007
Author(s)
Podar K, Raab MS, Tonon G, Sattler M, Barila D, Zhang J, Tai YT, Yasui H, Raje N, Depinho RA, Hideshima T, Chauhan D, Anderson KC
-
Journal Title
Cancer Res 67(4)
Pages: 1680-1688
Peer Reviewed
-
[Journal Article] JS-K, a GST-activated nitric oxide generator, induces DNA double strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.2007
Author(s)
Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC
-
Journal Title
Blood 110(2)
Pages: 709-18
Peer Reviewed
-
[Journal Article] KC, Carrasco DR. Targeting the {beta}-catenin/TCF transcriptional complex in the treatment of multiple myeloma.2007
Author(s)
Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC, Carrasco DR
-
Journal Title
Proc Natl Acad Sci U S A 104(18)
Pages: 7516-7521
Peer Reviewed
-
[Journal Article] 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.2007
Author(s)
Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC
-
Journal Title
Mol Cancer Ther 6(6)
Pages: 1718-27
Peer Reviewed
-
[Journal Article] MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.2007
Author(s)
Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson KC
-
Journal Title
Blood 110(10)
Pages: 3744-52
Peer Reviewed
-
[Journal Article] Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.2007
Author(s)
Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC
-
Journal Title
Br J Haematol 138(6)
Pages: 783-91
Peer Reviewed
-
[Journal Article] Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma.2007
Author(s)
Neri P, Tassone P, Shammas M, Yasui H, Schipani E, Batchu RB, Blotta S, Prabhala R, Catley L, Hamasaki M, Hideshima T, Chauhan D, Jacob GS, Picker D, Venuta S, Anderson KC, Munshi NC
-
Journal Title
Leukemia 21(12)
Pages: 2519-2526
Peer Reviewed
-
-
-